ERBB2 and glioblastoma: This clinical experience, along with the studies of EGFRvIII-CAR T cells and HER2-CAR T cells against glioblastoma provide initial evidence of the safety and antitumor activity of CAR T cell immunotherapy in patients with malignant brain tumors.